Abstract
Receptor tyrosine kinases (RTKs) are a family of cell surface receptors that play critical roles in signal transduction from extracellular stimuli. Many in this family of kinases are overexpressed or mutated in human malignancies and thus became an attractive drug target for cancer treatment. The signaling mediated by RTKs must be tightly regulated by interacting proteins including protein-tyrosine phosphatases and ubiquitin ligases. The suppressors of cytokine signaling (SOCS) family proteins are well-known negative regulators of cytokine receptors signaling consisting of eight structurally similar proteins, SOCS1–7, and cytokine-inducible SH2-containing protein (CIS). A key feature of this family of proteins is the presence of an SH2 domain and a SOCS box. Recent studies suggest that SOCS proteins also play a role in RTK signaling. Activation of RTK results in transcriptional activation of SOCS-encoding genes. These proteins associate with RTKs through their SH2 domains and subsequently recruit the E3 ubiquitin machinery through the SOCS box, and thereby limit receptor stability by inducing ubiquitination. In a similar fashion, SOCS proteins negatively regulate mitogenic signaling by RTKs. It is also evident that RTKs can sometimes bypass SOCS regulation and SOCS proteins can even potentiate RTKs-mediated mitogenic signaling. Thus, apart from negative regulation of receptor signaling, SOCS proteins may also influence signaling in other ways.
Similar content being viewed by others
References
Kazi JU, Kabir NN, Soh JW (2008) Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. Gene 410:147–153. doi:10.1016/j.gene.2007.12.003
Kabir NN, Kazi JU (2011) Comparative analysis of human and bovine protein kinases reveals unique relationship and functional diversity. Genet Mol Biol 34:587–591. doi:10.1590/S1415-47572011005000035
Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134. doi:10.1016/j.cell.2010.06.011
Kazi JU, Vaapil M, Agarwal S, Bracco E, Påhlman S, Rönnstrand L (2013) The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cell Signal 25:1852–1860. doi:10.1016/j.cellsig.2013.05.016
Kazi JU, Rönnstrand L (2013) FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. Mol Oncol 7:402–418. doi:10.1016/j.molonc.2012.11.003
Lin DC, Yin T, Koren-Michowitz M et al (2012) Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. Blood 120:3310–3317. doi:10.1182/blood-2011-10-388611
Kazi JU, Rönnstrand L (2012) Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling. PLoS One 7:e53509. doi:10.1371/journal.pone.0053509
Lennartsson J, Rönnstrand L (2012) Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 92:1619–1649. doi:10.1152/physrev.00046.2011
Masson K, Rönnstrand L (2009) Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 21:1717–1726. doi:10.1016/j.cellsig.2009.06.002
Yoshimura A, Ohkubo T, Kiguchi T et al (1995) A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 14:2816–2826
Masuhara M, Sakamoto H, Matsumoto A et al (1997) Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 239:439–446. doi:10.1006/bbrc.1997.7484
Endo TA, Masuhara M, Yokouchi M et al (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921–924. doi:10.1038/43213
Starr R, Willson TA, Viney EM et al (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917–921. doi:10.1038/43206
Hilton DJ, Richardson RT, Alexander WS et al (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95:114–119
Kile BT, Alexander WS (2001) The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 58:1627–1635
Kazi JU, Rönnstrand L (2013) Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol 7:693–703. doi:10.1016/j.molonc.2013.02.020
Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Rönnstrand L (2012) Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3. J Biol Chem 287:36509–36517. doi:10.1074/jbc.M112.376111
Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P (2004) Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem 279:12249–12259. doi:10.1074/jbc.M313381200
Kawazoe Y, Naka T, Fujimoto M et al (2001) Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 193:263–269
Jamieson E, Chong MM, Steinberg GR et al (2005) Socs1 deficiency enhances hepatic insulin signaling. J Biol Chem 280:31516–31521. doi:10.1074/jbc.M502163200
Wiejak J, Dunlop J, Gao S, Borland G, Yarwood SJ (2012) Extracellular signal-regulated kinase mitogen-activated protein kinase-dependent SOCS-3 gene induction requires c-Jun, signal transducer and activator of transcription 3, and specificity protein 3 transcription factors. Mol Pharmacol 81:657–668. doi:10.1124/mol.111.076976
Iglesias-Gato D, Chuan YC, Wikström P et al (2014) SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis 35:24–33. doi:10.1093/carcin/bgt304
Okochi O, Hibi K, Sakai M et al (2003) Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 9:5295–5298
He B, You L, Uematsu K et al (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100:14133–14138. doi:10.1073/pnas.2232790100
De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R (1999) Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J 18:904–915. doi:10.1093/emboj/18.4.904
Reddy PN, Sargin B, Choudhary C et al (2012) SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood 120:1691–1702. doi:10.1182/blood-2010-08-301416
Rottapel R, Ilangumaran S, Neale C et al (2002) The tumor suppressor activity of SOCS-1. Oncogene 21:4351–4362. doi:10.1038/sj.onc.1205537
Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394–42398. doi:10.1074/jbc.C200444200
Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–5446. doi:10.1128/MCB.24.12.5434-5446.2004
Bourette RP, De Sepulveda P, Arnaud S, Dubreuil P, Rottapel R, Mouchiroud G (2001) Suppressor of cytokine signaling 1 interacts with the macrophage colony-stimulating factor receptor and negatively regulates its proliferation signal. J Biol Chem 276:22133–22139. doi:10.1074/jbc.M101878200
Yu W, Chen J, Xiong Y et al (2008) CSF-1 receptor structure/function in MacCsf1r-/- macrophages: regulation of proliferation, differentiation, and morphology. J Leukoc Biol 84:852–863. doi:10.1189/jlb.0308171
Gui Y, Yeganeh M, Ramanathan S et al (2011) SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J Hepatol 55:1300–1308. doi:10.1016/j.jhep.2011.03.027
Hafizi S, Alindri F, Karlsson R, Dahlback B (2002) Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem Biophys Res Commun 299:793–800
Dey BR, Spence SL, Nissley P, Furlanetto RW (1998) Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem 273:24095–24101
Xia L, Wang L, Chung AS et al (2002) Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 277:30716–30723. doi:10.1074/jbc.M202823200
Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E (2006) Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 119:380–387. doi:10.1242/jcs.02740
Choudhary C, Brandts C, Schwable J et al (2007) Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110:370–374. doi:10.1182/blood-2006-05-024018
Gui Y, Yeganeh M, Cepero-Donates Y, Ramanathan S, Saucier C, Ilangumaran S (2013) Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma. Curr Pharm Des 19:1–12
Kazi JU, Agarwal S, Sun J, Bracco E, Rönnstrand L (2014) Src-like adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling. J Cell Sci 127:653–662. doi:10.1242/jcs.140590
Gulli LF, Palmer KC, Chen YQ, Reddy KB (1996) Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 7:173–178
Oveland E, Wergeland L, Hovland R, Lorens JB, Gjertsen BT, Fladmark KE (2012) Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biol Toxicol 28:201–212. doi:10.1007/s10565-012-9216-z
Greenhalgh CJ, Rico-Bautista E, Lorentzon M et al (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115:397–406. doi:10.1172/JCI22710
Vesterlund M, Zadjali F, Persson T et al (2011) The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels. PLoS One 6:e25358. doi:10.1371/journal.pone.0025358
Lopaczynski W (1999) Differential regulation of signaling pathways for insulin and insulin-like growth factor I. Acta Biochim Pol 46:51–60
Kazi JU, Kabir NN, Rönnstrand L (2013) Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia. Med Oncol 30:575. doi:10.1007/s12032-013-0757-7
Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I (2003) Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5:461–466. doi:10.1038/ncb983
Farabegoli F, Ceccarelli C, Santini D, Taffurelli M (2005) Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol 58:1046–1050. doi:10.1136/jcp.2004.024919
Goldshmit Y, Walters CE, Scott HJ, Greenhalgh CJ, Turnley AM (2004) SOCS2 induces neurite outgrowth by regulation of epidermal growth factor receptor activation. J Biol Chem 279:16349–16355. doi:10.1074/jbc.M312873200
Roberts AW, Robb L, Rakar S et al (2001) Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 98:9324–9329. doi:10.1073/pnas.161271798
Mori H, Hanada R, Hanada T et al (2004) Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 10:739–743. doi:10.1038/nm1071
Jo D, Liu D, Yao S, Collins RD, Hawiger J (2005) Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med 11:892–898. doi:10.1038/nm1269
Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985–15991
Emanuelli B, Peraldi P, Filloux C et al (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276:47944–47949. doi:10.1074/jbc.M104602200
Dey BR, Furlanetto RW, Nissley P (2000) Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun 278:38–43. doi:10.1006/bbrc.2000.3762
Zolotnik IA, Figueroa TY, Yaspelkis BB 3rd (2012) Insulin receptor and IRS-1 co-immunoprecipitation with SOCS-3, and IKKalpha/beta phosphorylation are increased in obese Zucker rat skeletal muscle. Life Sci 91:816–822. doi:10.1016/j.lfs.2012.08.038
Peraldi P, Filloux C, Emanuelli B, Hilton DJ, Van Obberghen E (2001) Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. J Biol Chem 276:24614–24620. doi:10.1074/jbc.M102209200
Sundaram K, Senn J, Reddy SV (2013) SOCS-1/3 participation in FGF-2 signaling to modulate RANK ligand expression in Paget’s disease of bone. J Cell Biochem 114:2032–2038. doi:10.1002/jcb.24554
Cacalano NA, Sanden D, Johnston JA (2001) Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol 3:460–465. doi:10.1038/35074525
Kario E, Marmor MD, Adamsky K et al (2005) Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 280:7038–7048. doi:10.1074/jbc.M408575200
Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S (2007) Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure 15:1493–1504. doi:10.1016/j.str.2007.09.016
Nicholson SE, Metcalf D, Sprigg NS et al (2005) Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci USA 102:2328–2333. doi:10.1073/pnas.0409675102
Linossi EM, Chandrashekaran IR, Kolesnik TB et al (2013) Suppressor of cytokine signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS One 8:e70536. doi:10.1371/journal.pone.0070536
Lai RH, Hsiao YW, Wang MJ et al (2010) SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett 288:75–85. doi:10.1016/j.canlet.2009.06.025
Sriram KB, Larsen JE, Savarimuthu Francis SM et al (2012) Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS One 7:e30398. doi:10.1371/journal.pone.0030398
Krebs DL, Uren RT, Metcalf D et al (2002) SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol 22:4567–4578
Li L, Grønning LM, Anderson PO et al (2004) Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism. J Biol Chem 279:34107–34114. doi:10.1074/jbc.M312672200
Mooney RA, Senn J, Cameron S et al (2001) Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276:25889–25893. doi:10.1074/jbc.M010579200
Hwang MN, Ha TH, Park J et al (2007) Increased SOCS6 stability with PMA requires its N-terminal region and the Erk pathway via Pkcdelta activation. Biochem Biophys Res Commun 354:184–189. doi:10.1016/j.bbrc.2006.12.175
Zadjali F, Pike AC, Vesterlund M et al (2011) Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem 286:480–490. doi:10.1074/jbc.M110.173526
Sitko JC, Guevara CI, Cacalano NA (2004) Tyrosine-phosphorylated SOCS3 interacts with the Nck and Crk-L adapter proteins and regulates Nck activation. J Biol Chem 279:37662–37669. doi:10.1074/jbc.M404007200
Matuoka K, Miki H, Takahashi K, Takenawa T (1997) A novel ligand for an SH3 domain of the adaptor protein Nck bears an SH2 domain and nuclear signaling motifs. Biochem Biophys Res Commun 239:488–492. doi:10.1006/bbrc.1997.7492
Martens N, Wery M, Wang P et al (2004) The suppressor of cytokine signaling (SOCS)-7 interacts with the actin cytoskeleton through vinexin. Exp Cell Res 298:239–248. doi:10.1016/j.yexcr.2004.04.002
Banks AS, Li J, McKeag L et al (2005) Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 115:2462–2471. doi:10.1172/JCI23853
Sasi W, Ye L, Jiang WG, Mokbel K, Sharma A (2013) Observations on the effects of suppressor of cytokine signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin like growth factor I (IGF-I). Clin Transl Oncol. doi:10.1007/s12094-013-1107-0
Krejci P, Prochazkova J, Bryja V et al (2009) Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal 21:151–160. doi:10.1016/j.cellsig.2008.10.006
Chen S, Anderson PO, Li L, Sjögren HO, Wang P, Li SL (2003) Functional association of cytokine-induced SH2 protein and protein kinase C in activated T cells. Int Immunol 15:403–409
Raccurt M, Tam SP, Lau P et al (2003) Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer 89:524–532. doi:10.1038/sj.bjc.6601115
Sasi W, Jiang WG, Sharma A, Mokbel K (2010) Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer 10:178. doi:10.1186/1471-2407-10-178
Li Z, Metze D, Nashan D et al (2004) Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 123:737–745. doi:10.1111/j.0022-202X.2004.23408.x
Zhang J, Li H, Yu JP, Wang SE, Ren XB (2012) Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer 130:1971–1980. doi:10.1002/ijc.27318
Mottok A, Renne C, Seifert M et al (2009) Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood 114:4503–4506. doi:10.1182/blood-2009-06-225839
Hanada T, Kobayashi T, Chinen T et al (2006) IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203:1391–1397. doi:10.1084/jem.20060436
Weniger MA, Melzner I, Menz CK et al (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25:2679–2684. doi:10.1038/sj.onc.1209151
Hiwatashi K, Tamiya T, Hasegawa E et al (2011) Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Lett 308:172–180. doi:10.1016/j.canlet.2011.04.024
Qiu X, Zheng J, Guo X et al (2013) Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Mol Cell Biochem 378:99–106. doi:10.1007/s11010-013-1599-5
Zhu JG, Dai QS, Han ZD et al (2013) Expression of SOCSs in human prostate cancer and their association in prognosis. Mol Cell Biochem 381:51–59. doi:10.1007/s11010-013-1687-6
Iglesias-Gato D, Chuan YC, Wikström P et al (2013) SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis. doi:10.1093/carcin/bgt304
Niwa Y, Kanda H, Shikauchi Y et al (2005) Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24:6406–6417. doi:10.1038/sj.onc.1208788
Zhang L, Li J, Li L et al (2014) IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis. doi:10.1093/carcin/bgu017
Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S (2002) Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100:2926–2931. doi:10.1182/blood-2002-01-0073
Suessmuth Y, Elliott J, Percy MJ et al (2009) A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol 147:450–458. doi:10.1111/j.1365-2141.2009.07860.x
Quentmeier H, Geffers R, Jost E et al (2008) SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22:2169–2175. doi:10.1038/leu.2008.226
Jost E, ON do, Dahl E et al (2007) Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 21:505–510. doi:10.1038/sj.leu.2404513
Etienne A, Carbuccia N, Adelaide J et al (2007) Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet Cytogenet 176:80–88. doi:10.1016/j.cancergencyto.2007.03.009
Fourouclas N, Li J, Gilby DC et al (2008) Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 93:1635–1644. doi:10.3324/haematol.13043
Haan S, Ferguson P, Sommer U et al (2003) Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem 278:31972–31979. doi:10.1074/jbc.M303170200
Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 101:10422–10427. doi:10.1073/pnas.0402511101
Ueki K, Kadowaki T, Kahn CR (2005) Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 33:185–192. doi:10.1016/j.hepres.2005.09.032
Kato H, Nomura K, Osabe D et al (2006) Association of single-nucleotide polymorphisms in the suppressor of cytokine signaling 2 (SOCS2) gene with type 2 diabetes in the Japanese. Genomics 87:446–458. doi:10.1016/j.ygeno.2005.11.009
Ramos MI, Perez SG, Aarrass S et al (2013) FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis. Arthritis Res Ther 15:R209. doi:10.1186/ar4403
Madan B, Goh KC, Hart S et al (2012) SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. J Immunol 189:4123–4134. doi:10.4049/jimmunol.1200675
Juurikivi A, Sandler C, Lindstedt KA et al (2005) Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 64:1126–1131. doi:10.1136/ard.2004.029835
Tsao JT, Kuo CC, Lin SC (2008) The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Clin Exp Med 8:179–185. doi:10.1007/s10238-008-0006-0
Chen YH, Hsieh SC, Chen WY et al (2011) Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFbeta1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann Rheum Dis 70:1655–1663. doi:10.1136/ard.2010.145821
De Souza D, Fabri LJ, Nash A, Hilton DJ, Nicola NA, Baca M (2002) SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41:9229–9236
Puissant A, Fenouille N, Alexe G et al (2014) SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 25:226–242. doi:10.1016/j.ccr.2014.01.022
Kabir NN, Kazi JU (2014) Grb10 is a dual regulator of receptor tyrosine kinase signaling. Mol Biol Rep. doi:10.1007/s11033-014-3046-4
Neuwirt H, Puhr M, Santer FR et al (2009) Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol 174:1921–1930. doi:10.2353/ajpath.2009.080751
Acknowledgments
This research was funded by the Swedish Cancer Society (LR), the Swedish Childhood Cancer Foundation (LR), the Swedish Research Council (LR), ALF governmental clinical grant (LR), Stiftelsen Olle Engkvist Byggmästare (JUK), the Royal Physiographic Society in Lund (JUK), Ollie och Elof Ericssons Stiftelse (JUK) and The Lars Hierta Memorial Foundation (JUK).
Conflict of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kazi, J.U., Kabir, N.N., Flores-Morales, A. et al. SOCS proteins in regulation of receptor tyrosine kinase signaling. Cell. Mol. Life Sci. 71, 3297–3310 (2014). https://doi.org/10.1007/s00018-014-1619-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-014-1619-y